Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnovivaINVA +1.08%86 EV-to-EBIT is 2.84 as of Aug. 19, 2026, which is 59% below its 10-year median of 6.88. GuruFocus rates INVA with a GF Score™ of 86/100 and a GF Value™ of $23.25 (Fairly Valued). The stock has 2 warning signs investors should review. Among 369 Biotechnology companies, Innoviva ranks better than 71.27% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Innoviva's Enterprise Value for the quarter that ended in Jun. 2026 was $1,340.2 Mil.
Innoviva's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $437.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva EV-to-EBIT Related Terms
Innoviva EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Innoviva's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innoviva's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innoviva EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innoviva's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Innoviva's EV-to-EBIT falls into.
Innoviva's current Enterprise Value is $1,242.4 Mil.
Innoviva's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $437.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva (INVA) has a EV-to-EBIT of 2.84 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Innoviva and its competitors. This is 59% below median its historical median of 6.88. According to the industry distribution chart, Innoviva ranks #106 out of 369 companies in the Biotechnology industry, placing it in the top 28.7%.
Is Innoviva's EV-to-EBIT too high?
Innoviva's current EV-to-EBIT of 2.84 is 59% below median its 10-year median of 6.88. The Biotechnology industry median EV-to-EBIT is 15.95. Innoviva's value of 2.84 is 82.2% below this industry median. Based on the distribution chart, Innoviva ranks #106 out of 369 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Innoviva has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innoviva's EV-to-EBIT compare to TSHA and MLTX?
According to the Biotechnology industry distribution chart, Innoviva ranks #106 out of 369 companies for EV-to-EBIT. This puts Innoviva in the upper half of its industry. The industry median EV-to-EBIT is 15.95. Innoviva's value of 2.84 is 82.2% below this benchmark. While the company's 10-year median is 6.88 vs. the industry median of 15.95, Innoviva has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innoviva's current EV-to-EBIT of 2.84 is 82.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Innoviva and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innoviva's current EV-to-EBIT is 2.84, which is 59% below median its own 10-year median of 6.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innoviva stock overvalued right now?
Based on GuruFocus' analysis, Innoviva (INVA) is currently considered Fairly Valued. The stock's GF Value™ is $23.25, compared to a current price of $21.48 — trading 7.6% below its estimated fair value. The current EV-to-EBIT is 2.84, which is 59% below median its 10-year median of 6.88 and 82.2% below the Biotechnology industry median of 15.95. Innoviva's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Innoviva (INVA), the current EV-to-EBIT is 2.84 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innoviva (INVA) Overvalued in 2026?
Based on GuruFocus' analysis, Innoviva stock appears to be undervalued.
The current stock price of $21.48 is trading 7.6% below its estimated GF Value™ of $23.25.
GuruFocus considers Innoviva to be Fairly Valued.
Key valuation signals for INVA:
EV-to-EBIT: 2.84 (59% below median its 10-year median of 6.88)
GF Value™: $23.25 vs. price of $21.48 (7.6% below fair value)
Industry Position: 82.2% below the Biotechnology median (#106 of 369)
No single metric tells the full story. See the INVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
86GF Score
Get the complete analysis for INVA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INVA has been successfully added to your 
